Welcome to our dedicated page for Pelthos Therapeutics news (Ticker: PTHS), a resource for investors and traders seeking the latest updates and insights on Pelthos Therapeutics stock.
Pelthos Therapeutics Inc. (PTHS) generates news primarily around its commercial dermatology portfolio and corporate development activities. As a biopharmaceutical company focused on therapeutic products for unmet patient needs, much of its coverage relates to the launch and market uptake of ZELSUVMI (berdazimer) topical gel, 10.3%, an FDA-approved at-home treatment for molluscum contagiosum in adults and pediatric patients one year of age and older.
Investors following Pelthos can expect regular updates on product commercialization milestones, including prescription trends, prescriber adoption, and payer access for ZELSUVMI. Company press releases have highlighted commercial agreements with pharmacy benefit managers and group purchasing organizations that expand formulary coverage and patient access, as well as educational initiatives such as the Moms Against Molluscum movement aimed at caregivers managing molluscum contagiosum.
News flow also covers portfolio expansion. Pelthos has announced acquisitions of Xepi (ozenoxacin) Cream, 1%, an FDA-approved topical treatment for impetigo, and Xeglyze (abametapir), an FDA-approved topical treatment for head lice infestation. These transactions, together with planned product relaunch timelines, feature prominently in company communications as Pelthos builds a broader cutaneous infectious disease franchise.
On the corporate and financial side, Pelthos issues releases on quarterly financial results, private financings, and credit facilities. Examples include senior secured convertible notes with investors including Ligand Pharmaceuticals and a senior secured term loan facility with Horizon Technology Finance Corporation, both described as supporting commercialization of ZELSUVMI and the integration of additional products. Governance and investor relations updates, such as board appointments and participation in healthcare and investor conferences, also appear in the company’s news stream.
For readers and investors, the Pelthos news page offers a consolidated view of these developments, providing context on how the company is executing its strategy in molluscum contagiosum, impetigo, and head lice, and how financing and partnerships are aligned with its commercial objectives.
Pelthos Therapeutics (NYSE American: PTHS) reported second quarter 2026 Zelsuvmi® net product revenue of $15.4 million, up 45% from $10.7 million in the first quarter. Total revenue was $15.6 million. Zelsuvmi units dispensed rose 48% quarter-over-quarter to 11,925 from 8,084, with 4,571 unique prescribers in the quarter.
Since its July 2025 launch, Zelsuvmi has generated $42.3 million in net sales, with 29,126 units dispensed and more than 25,000 patients treated. Pelthos ended June 30, 2026 with $24.2 million in cash and a $50 million Horizon term loan facility, $30 million drawn and potential access to an additional $10 million. Net loss was $23.4 million in Q2 2026 versus $25.1 million in Q1, and Adjusted EBITDA was a loss of $5.7 million versus $8.0 million. Total liabilities were $138.9 million and stockholders’ equity was a $1.5 million deficit.
Pelthos Therapeutics (NYSE American: PTHS) announced it will report its second quarter 2026 financial results on Thursday, August 13, 2026, and will host a conference call with a Q&A session at 8:30 a.m. Eastern Time. Investors can join via toll-free and international dial-in numbers or through a live webcast.
Pelthos Therapeutics (NYSE American: PTHS) announced that its 2026 Annual Meeting of Stockholders will be held virtually on Tuesday, September 29, 2026 at 9:00 a.m. Eastern Time. Stockholders of record at the close of business on August 4, 2026 may vote at the meeting.
Pelthos expects to file its Notice of Annual Meeting and proxy statement in early August 2026. Because the 2026 meeting date is more than 30 days from the 2025 meeting anniversary, stockholder proposals under Rule 14a-8 must be received by August 3, 2026 for inclusion in the proxy materials.
Pelthos Therapeutics (NYSE American:PTHS) has been added to the Russell 3000E Growth Benchmark, Russell Microcap, and Russell Microcap Growth Benchmark indexes, effective with the US market open on June 29, 2026, following the 2026 Russell US Indexes reconstitution.
The Russell US Indexes capture up to 4,000 largest US stocks by market cap and are reconstituted semi-annually. According to Pelthos, inclusion may enhance its visibility as about $12.2 trillion in assets are benchmarked against Russell US indexes.
Pelthos Therapeutics (NYSE American:PTHS) announced that CEO Scott Plesha will present at the 2026 Jefferies Global Healthcare Conference in New York. The presentation is scheduled for 11:05 a.m. ET on June 4, 2026, followed by one-on-one investor meetings arranged through Jefferies representatives.
Pelthos Therapeutics (NYSE American:PTHS) reported first quarter 2026 results highlighted by continued growth of ZELSUVMI, its at‑home molluscum contagiosum treatment. ZELSUVMI net product revenue rose to $10.7 million from $9.1 million in Q4 2025, with units dispensed up 25% quarter over quarter.
Since launch in July 2025, ZELSUVMI has generated $26.9 million in net sales from 16,774 units. The sales force expanded from 50 to 64 territory managers. Pelthos entered a $50 million senior secured term loan with Horizon, drawing $30 million. Q1 2026 net loss was $(10.2) million versus $(21.7) million in Q4 2025; adjusted EBITDA was $(8.0) million. Cash was $32.0 million at March 31, 2026, with approximately 8.9 million shares outstanding on an as‑converted basis.
Pelthos Therapeutics (NYSE American: PTHS) will report first quarter 2026 financial results on Thursday, May 14, 2026 and hold a conference call at 8:30 a.m. Eastern Time. The call includes a Q&A and will be accessible by phone (Conf. ID 13760399) and live webcast.
Dial-in numbers and the webcast link are provided for investor access.
Pelthos Therapeutics (NYSE American: PTHS) announced that CEO Scott Plesha will attend one-on-one investor meetings at the Piper Sandler Spring Biopharma Symposium on April 16, 2026 in Boston. Investors should contact their Piper Sandler representative to arrange meetings.
Pelthos Therapeutics (NYSE American: PTHS) appointed John M. Gay as Chief Financial Officer effective April 10, 2026. Mr. Gay, previously Senior Vice President, Finance & Accounting since 2025, brings more than 25 years of public company finance and accounting experience.
He succeeds Francis Knuettel II, who served as CFO since July 2025. Management thanked the outgoing CFO for contributions tied to the merger with Channel Therapeutics and two recent significant capital raises.
Pelthos Therapeutics (NYSE American: PTHS) announced the first patient has been dosed in a placebo-controlled Phase 1b/2a trial of CT2000, an ophthalmic NaV1.7 inhibitor for acute and chronic eye pain. The adaptive study includes ascending-dose Phase 1 and a 28-day Phase 2a MTD period. Results are anticipated by end of 2026. Channel, a Pelthos subsidiary, reported meeting predefined preclinical endpoints for CT2000 in May 2025. The company notes a global chronic ocular pain market estimate of $5.3 billion by 2032.